Attachment_No._01-Purchase_Description_Promega_P450-Glo.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose: The Tox21 group (NCATS) requires P450-Glo assay systems (CYP3A4 with Luciferin-PPXE, CYP2D6, and CYP1A2). These assay kits will be used to screen compounds from Tox21 collaboration.

2. Background Information and Objective: Tox21 collaboration between NCATS (then NCGC), NTP, EPA and FDA started with an aim to screen tens of thousands of known drugs and compounds in vitro by reducing the cost and time consuming processes involved in traditional toxiciticy testing methods. Since its inception nearly a decade ago, several screenings against Tox21 compound collection were performed at NCATS by running cell-based assays focused mainly on different targets and toxicity pathways which included nuclear receptor signaling, stress response, developmental toxicology, GPCR/cAMP signaling, and Epigentics etc. All these assays used either luciferase or fluorescence reporter gene technology for readouts. In order to quanitfy the induction/inhibiton of these reporter gene activities, different detection assay systems have been used.

Currently we are testing P450-Glo assay systems to eventually screen the Tox21 libraries for testing the effects of drugs and chemical entities on cytochrome P450 enzyme activities.

3. Generic Name of Product: Assay screening system kits.

4. Purchase Description:

Item No. V9910. Quantity: sixty-five (65) units.

Description: P450-Glo CYP3A4 screening system with Luciferin-PPXE.

Item No. V9890. Quantity: sixty-five (65) units.

Description: P450-Glo CYP2D6 screening system.

Item No. V9770. Quantity: sixty-five (65) units.

P450-Glo CYP1A2 screening system.

5. Salient characteristics:

P450-Glo CYP3A4 with Luciferin-PPXE, CYP2D6, and CYP1A2 assay systems:

• These assays are homogeneous, luminescent method for measuring cytochrome

P450 CYP3A4, CYP2D6, and CYP1A2 activities.

• These assays exhibit exquisite sensitivity, low background signals, and broad dynamic range.

Solicitation No. NIHDA201800410

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

• The half-life of the luminescent output is greater than two hours, eliminating the need for luminometers with injectors and allowing batch plate processing.

• The formulation also minimizes the incidence of false positives due to inhibition of luciferase by analytes when screening for cytochrome P450 inhibitors.

• The luminescent format also eliminates the need for time-consuming analyses.

• These assays has the reduced incubation times as the luciferin-based substrates are readily taken up by cells and rapidly converted to luciferin insided the cell.

• These assays are very stable for a number of thaw and freeze cycles.

6. Quantity: One hundred ninety-five (195) total assay systems consisting of the following:

Sixty-five (65) units of the P450-Glo CYP3A4 screening system with Luciferin-PPXE.

Sixty-five (65) units of the P450-Glo CYP2D6 screening system.

Sixty-five (65) units of the P450-Glo CYP1A2 screening system.

7. Delivery Date: Delivery shall be within one to three (1-3) days after receipt of order (ARO) for assay system kits.

The assay system kits shall be delivered to:

Attn: Menghang Xia

NCATS

9800 Medical Center Drive Building C, Room C335 Rockville, MD 20850 Loading Dock call: 301-217-5735

Solicitation No. NIHDA201800410